Yu Xianjun, Zhang Yuqing, Chen Changyi, Yao Qizhi, Li Min
Michael E. DeBakey Department of Surgery, Molecular Surgeon Research Center, Elkins Pancreas Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Biochim Biophys Acta. 2010 Jan;1805(1):97-104. doi: 10.1016/j.bbcan.2009.10.001. Epub 2009 Oct 22.
Effective drug delivery in pancreatic cancer treatment remains a major challenge. Because of the high resistance to chemo and radiation therapy, the overall survival rate for pancreatic cancer is extremely low. Recent advances in drug delivery systems hold great promise for improving cancer therapy. Using liposomes, nanoparticles, and carbon nanotubes to deliver cancer drugs and other therapeutic agents such as siRNA, suicide gene, oncolytic virus, small molecule inhibitor, and antibody has been a success in recent preclinical trials. However, how to improve the specificity and stability of the delivered drug using ligand or antibody directed delivery represent a major problem. Therefore, developing novel, specific, tumor-targeted drug delivery systems is urgently needed for this terrible disease. This review summarizes the current progress on targeted drug delivery in pancreatic cancer and provides important information on potential therapeutic targets for pancreatic cancer treatment.
在胰腺癌治疗中实现有效的药物递送仍然是一项重大挑战。由于对化疗和放疗具有高度抗性,胰腺癌的总体生存率极低。药物递送系统的最新进展为改善癌症治疗带来了巨大希望。在最近的临床前试验中,使用脂质体、纳米颗粒和碳纳米管来递送癌症药物以及其他治疗剂(如小干扰RNA、自杀基因、溶瘤病毒、小分子抑制剂和抗体)已取得成功。然而,如何利用配体或抗体导向递送提高所递送药物的特异性和稳定性是一个主要问题。因此,对于这种可怕的疾病,迫切需要开发新型、特异性的肿瘤靶向药物递送系统。本综述总结了胰腺癌靶向药物递送的当前进展,并提供了有关胰腺癌治疗潜在治疗靶点的重要信息。